[ad_1]
August 2, 2019 – The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure that is relaxing some radiopharmaceutical bundling practices and simplifying the billing of Medicare for nuclear medicine procedures.
According to the law, diagnostic radiopharmaceuticals are drugs, but despite concerns about increasing patient access issues, Medicare Centers and Medicaid Services (CMS) treat them as supplies and package them into packages of procedures. The combination of radiopharmaceuticals has proven problematic, as the costs of radiopharmaceuticals for diagnostic purposes can vary considerably from one nuclear medicine procedure to another, according to the ASRT.
The company added that the current process discourages hospitals from using innovative and targeted radiopharmaceuticals, limits investments in the search for new radiopharmaceutical products for research purposes and can hinder patients' access to tools. the most appropriate diagnostics in easily accessible health facilities. In addition, this can also lead to inaccurate diagnoses and ineffective treatment plans.
HR 3772, the ASRT, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the Alliance of Technology and Medical Imaging (MITA) and the Radionuclide Council and radiopharmaceuticals
Read the full text of the resolution.
For more information: www.asrt.org
Source link
